Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with 6 novel non-opioid products in development to treat pain, both in the U.S. and around the world. The Company aims to address shortfalls of current pain management treatments by developing and commercializing effective and safe, non-opioid options without the risks of abuse, misuse, and diversion seen with opioids, or the opioid-induced side effects, including potentially life-threatening respiratory depression.
Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to moderately severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion.
Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.
Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to moderately severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion.
Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.
Location: United States, New Jersey, Morristown
Employees: 1-10
Total raised: $6M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | HCL Capita... | hcl-capita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2017 | Series A | $6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 26.07.2022 | Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre | All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the ... |
| 21.09.2018 | Neumentum Raises Funding from AngelMD | Neumentum, Inc., a California-based company that is developing and plans to commercialize products to treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics, raised funding from AngelMD, an investment and n... |
| 07.12.2017 | Term Sheet — Thursday December 7 | GOING GLOBAL Good morning again from Guangzhou, China. Paid Content Securing the enterprise without boundaries From ExtraHop “The backlash against globalization happens because many people feel left behind,” he said. “Closing our doors will... |
| 06.12.2017 | Neumentum Raises $6M in Series A Funding | Neumentum, a Palo Alto, California-based developer of non-opioid pain products for acute and chronic pain, raised $6m in Series A funding. The backers were not disclosed. Brookline Capital Markets acted as the exclusive placement agent for ... |